A total of 43 innovative new medicines are anticipated to be approved or listed in Japan this year, according to a survey by Jiho. At the center of attention are some highly innovative, but probably ultra-expensive, gene therapies, as well…
ORGANIZATION
It’s Time to Revise G1 Withdrawal Scheme, Rule Likely to Be Applied to Only a Few Products: FPMAJ
The time has come to revise the so-called G1 withdrawal scheme for long-listed products (LLPs), with only a few medicines expected to exit the market when the rule is first implemented in 2024, the Federation of Pharmaceutical Manufacturers’ Associations of…
To read the full story
Related Article
- FPMAJ Urges More Precise Handling of CEA Price Tweaks for Products with “Cost Increase” Profile
June 13, 2022
- 4-Year Grace Period Was Good News, but More Should Be Done for Re-Pricing Exclusion: FPMAJ
June 13, 2022
- FPMAJ Pushes Minimal Product Scope for Off-Year Re-Pricing, No Cut in 2% Buffer Zone: Annual Report
June 13, 2022
- MHLW Reveals Details of New Withdrawal Rules for Off-Patent Branded Drugs
April 1, 2019
ORGANIZATION
- JPMA Exec Urges Rethink of Social Security Funding; Comments on Trump’s Policy
January 24, 2025
- Japan Biosimilar Association Ready to Play Its Roles under Govt Roadmap
January 17, 2025
- JGA to Launch Scheme for Requesting Production Ramp-Up in March: President
January 14, 2025
- Drug Price Cuts for 8 Years Straight Is Big Burden: Trade Group Chief
January 9, 2025
- Pharma CEOs Discouraged by Off-Year Revision, but Give Certain Credit to Category-Based Scope
January 9, 2025
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…